MaxCyte, Inc. Signing of Strategic Platform License (5209I)
December 05 2022 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 5209I
MaxCyte, Inc.
05 December 2022
MaxCyte Signs Strategic Platform License with Curamys to Enable
Cell & Gene Therapies for the Treatment of Rare Intractable
Diseases
Curamys to use MaxCyte's Flow Electroporation(R) technology and
ExPERT(TM) platform to help advance its cell fusion technology.
ROCKVILLE, MD, and SEOUL, South Korea December 5, 2022 -
MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and to
support innovative, cell-based research, and Curamys , a South
Korean biotechnology company that develops cell & gene therapy
using cell fusion technology to treat rare intractable diseases,
including Duchenne muscular dystrophy and amyotrophic lateral
sclerosis, today announced the signing of a strategic platform
license (SPL).
Under the terms of the agreement, Curamys obtains non-exclusive
clinical and commercial rights to use MaxCyte's Flow
Electroporation(R) technology and ExPERT(TM) platform. In return,
MaxCyte is entitled to receive platform licensing fees and
program-related revenue.
Curamys is focused on developing treatments for genetic and
degenerative diseases through its specialized cell fusion
technology, based on the concept that apoptotic or dying cells can
be regenerated by fusing them with healthy normal cells. Cell
fusion technology can function as a form of gene therapy when the
normal copies of genes existing in treatment cells are transferred
to dying cells, resulting in the development of a treatments for
genetic and rare intractable diseases at the cellular level.
"A recent report estimates that there are more than 10,000
distinct rare diseases affecting 400 million people around the
world ," said Doug Doerfler, President and CEO of MaxCyte. "Many of
these diseases, like ALS and DMD, have few or no treatments. We are
honored to support Curamys' efforts to develop its cell-fusion
technology for novel cell-based treatments that provide hope and
new options to patients and their families."
"At Curamys, our goal is to use cell fusion-based technologies
to transform the biomedical sciences by helping to identify genetic
factors contributing to numerous rare diseases with unknown medical
causes," said Dr. Jung Joon Sung, CEO of Curamys. "MaxCyte's
Platform will enable us to advance this technology so we can expand
our global reach and ultimately, help more patients living with
rare diseases."
MaxCyte's ExPERT(TM) instrument portfolio is the next generation
of leading, clinically-validated electroporation technology for
complex and scalable cell engineering. By delivering high
transfection efficiency, seamless scalability and enhanced
functionality, the ExPERT(TM) platform delivers the high-end
performance essential to enabling the next wave of biological and
cellular therapeutics. Curamys is MaxCyte's 18th SPL overall, which
generate pre-commercial milestone revenue and the vast majority of
which include post-commercial revenue.
About MaxCyte
MaxCyte is a leading, cell-engineering focused company providing
enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell
therapeutics and to support innovative, cell-based research. Over
the past 20 years, we have developed and commercialized our
proprietary Flow Electroporation(R) technology, which facilitates
complex engineering of a wide variety of cells. Our ExPERT(TM)
platform, which is based on our Flow Electroporation technology,
has been designed to support the rapidly expanding cell therapy
market and can be utilized across the continuum of the high-growth
cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The
ExPERT family of products includes: four instruments, the ATx(TM),
STx(TM) GTx(TM) and VLx(TM); a portfolio of proprietary related
processing assemblies or disposables; and software protocols, all
supported by a robust worldwide intellectual property portfolio.
Learn more at maxcyte.com and follow us on Twitter and LinkedIn
.
About Curamys
Curamys is a biotechnology company that develops cell & gene
therapeutics intended to offer treatment for rare intractable
diseases. The company's platform uses cell fusion technology - a
novel approach that allows the healthiest and youngest cells to
find apoptotic (diseased or dying) cells and fuse together so the
apoptotic cells can heal. This technology can be combined with stem
cell therapy to develop a therapeutic agent, and it can be used for
finding the causes of intractable diseases at the cellular level
enabling healthcare professionals to treat certain rare genetic
diseases. Currently, Curamys is devoted to develop therapeutics for
the treatment of rare diseases, including Duchenne muscular
dystrophy, Lou Gehrig's disease (i.e., amyotrophic lateral
sclerosis), and nonketotic hyperglycinemia . Learn more at
curamys.com .
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
jr@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
Consilium Strategic Communications
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
Curamys Contact
David Lee, CDO
david.lee@curamys.co.kr
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCTIBLTMTTMBFT
(END) Dow Jones Newswires
December 05, 2022 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Sep 2023 to Sep 2024